[at Bloomberg] - Dendreon Corp., the drugmaker whose market value has shrunk by more than half since August, is seeking a buyer after sales of its prostate-cancer treatment failed to meet expectations, said people familiar ...
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment